U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H21ClO4
Molecular Weight 360.831
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Fenofibrate

SMILES

CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(Cl)C=C2

InChI

InChIKey=YMTINGFKWWXKFG-UHFFFAOYSA-N
InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3

HIDE SMILES / InChI
Molecular Formula C20H21ClO4
Molecular Weight 360.831
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25903954

Fenofibrate is a drug of the fibrate class. It is mainly used to reduce cholesterol levels in people at risk of cardiovascular disease. It’s used as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Fenofibrate is a fibric acid derivative, a prodrug comprising fenofibric acid linked to an isopropyl ester. Fenofibrate is rapidly hydrolyzed after oral ingestion to its pharmacologically active form, fenofibric acid. The effects of fenofibric acid seen in clinical practice have been explained in vivo in transgenic mice and in vitro in human hepatocyte cultures by the activation of peroxisome proliferator activated receptor α (PPARα). It lowers lipid levels by activating peroxisome proliferator-activated receptor alpha (PPARα). PPARα activates lipoprotein lipase and reduces apoprotein CIII (an inhibitor of lipoprotein lipase activity), which increases lipolysis and elimination of triglyceride-rich particles from plasma. The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles (which are thought to be atherogenic due to their susceptibility to oxidation), to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly. PPARα also increases apoproteins AI and AII, reduces VLDL- and LDL-containing apoprotein B, and increases HDL-containing apoprotein AI and AII.Fenofibrate also reduces serum uric acid levels in hyperuricemic and normal individuals by increasing the urinary excretion of uric acid. Fenofibrate also has an off-label use as uricosuric therapy in people who have gout.

CNS Activity

CNS Non-penetrant
1040
Curator's Comment: fenofbrate cannot cross the blood-brain barrier and reach the central nervous system

Originator

Laboratoires Fournier
1
Curator's Comment: Procetofen was synthesized in 1974 and was introduced in clinical practice in France the same year. Procetofen, which significantly decreased plasma lipid concentrations in hyperlipidemic patients, was later called fenofibrate to comply with World Health Organization nomenclature guidelines

Approval Year

1993
138
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8583
TRICOR

Approved Use

Treatment of Hypercholesterolemia. TRICOR is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Treatment of Hypertriglyceridemia: TRICOR is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention.

Launch Date

2004
Palliative
Approved
8583
TRICOR

Approved Use

Treatment of Hypercholesterolemia. TRICOR is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Treatment of Hypertriglyceridemia: TRICOR is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention.

Launch Date

2004
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.96 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27648957
67 mg single, oral
dose: 67 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOFIBRIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
51.9 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27648957
67 mg single, oral
dose: 67 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOFIBRIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
22.1 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27648957
67 mg single, oral
dose: 67 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOFIBRIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
16 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021350s013lbl.pdf
160 mg 1 times / day multiple, oral
dose: 160 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FENOFIBRIC ACID serum
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021350s013lbl.pdf
160 mg 1 times / day multiple, oral
dose: 160 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FENOFIBRIC ACID serum
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
unhealthy, 49.5
Health Status: unhealthy
Age Group: 49.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
Other AEs: Asthenia, Pain...
Other AEs:
Asthenia (1.1%)
Pain (1.1%)
Headache (3.4%)
Migraine (2.3%)
Dyspepsia (2.3%)
Gastrointestinal disorder (1.1%)
Nausea (3.4%)
Diarrhoea (1.1%)
Myalgia (1.1%)
Dizziness (1.1%)
Abnormal thinking (1.1%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
Other AEs: Abdominal pain, Back pain...
Other AEs:
Abdominal pain (4.6%)
Back pain (3.4%)
Headache (3.2%)
Nausea (2.3%)
Constipation (2.1%)
Abnormal liver function tests (7.5%)
ALT increased (3%)
CPK increased (3%)
AST increased (3.4%)
Respiratory disorder (6.2%)
Rhinitis (2.3%)
Urticaria (1.1%)
Rash (1.4%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
200 mg 2 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 200 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7225166/
unhealthy
Health Status: unhealthy
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/7225166/
Sources:
https://pubmed.ncbi.nlm.nih.gov/7225166/
AEs

AEs

AESignificanceDosePopulation
Abnormal thinking 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
unhealthy, 49.5
Health Status: unhealthy
Age Group: 49.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
Asthenia 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
unhealthy, 49.5
Health Status: unhealthy
Age Group: 49.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
Diarrhoea 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
unhealthy, 49.5
Health Status: unhealthy
Age Group: 49.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
Dizziness 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
unhealthy, 49.5
Health Status: unhealthy
Age Group: 49.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
Gastrointestinal disorder 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
unhealthy, 49.5
Health Status: unhealthy
Age Group: 49.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
Myalgia 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
unhealthy, 49.5
Health Status: unhealthy
Age Group: 49.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
Pain 1.1%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
unhealthy, 49.5
Health Status: unhealthy
Age Group: 49.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
Dyspepsia 2.3%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
unhealthy, 49.5
Health Status: unhealthy
Age Group: 49.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
Migraine 2.3%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
unhealthy, 49.5
Health Status: unhealthy
Age Group: 49.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
Headache 3.4%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
unhealthy, 49.5
Health Status: unhealthy
Age Group: 49.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
Nausea 3.4%
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
unhealthy, 49.5
Health Status: unhealthy
Age Group: 49.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028504/
Urticaria 1.1%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
Rash 1.4%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
Constipation 2.1%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
Nausea 2.3%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
Rhinitis 2.3%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
ALT increased 3%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
CPK increased 3%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
Headache 3.2%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
AST increased 3.4%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
Back pain 3.4%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
Abdominal pain 4.6%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
Respiratory disorder 6.2%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
Abnormal liver function tests 7.5%
145 mg 1 times / day multiple, oral
Recommended
Dose: 145 mg, 1 times / day
Route: oral
Route: multiple
Dose: 145 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2252
inhibitor
2438
inhibitor
2507

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2C8
1057

CYP2E1
1060

CYP1A2
2153

CYP2C19
2057

CYP2A6
879

P-gp
1741

BCRP
910

OATP1B1
1079

BSEP
550
P-gp
2052

UGT1A9
423

AKR1C1
22

AKR1C2
12

AKR1C3
13

AKR1B1
1
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
2497
 moderate
CYP1A2
2333
 no
CYP2D6
2546
 no
CYP2E1
1146
 no
CYP3A4
2633
 no
CYP2A6
911
 weak
CYP2C19
2141
 weak
BCRP
985
 yes [IC50 170 uM]
CYP2C8
1117
 yes [IC50 2.39 uM]
P-gp
1932
 yes [IC50 5.83 uM]
BSEP
554
 yes [Inhibition 50 uM]
OATP1B1
1095
 yes [Ki 105.2 uM]
CYP7A1
7
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
P-gp
2052
 no
AKR1B1
1
 yes
AKR1C1
22
 yes
AKR1C2
12
 yes
AKR1C3
13
 yes
UGT1A9
423
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:5001
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5001
ChemicalBook
CB8266802
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8266802
eMolecules
538429
https://www.emolecules.com/cgi-bin/more?vid=538429
MolPort
MolPort-002-887-051
https://www.molport.com/shop/molecule-link/MolPort-002-887-051
Selleck Chemicals
Fenofibrate(Tricor)
http://www.selleckchem.com/products/Fenofibrate(Tricor).html
ZINC
ZINC000000584092
http://zinc15.docking.org/substances/ZINC000000584092
PubMed

PubMed

TitleDatePubMed
Amelioration of high fructose-induced metabolic derangements by activation of PPARalpha.
2002-05
Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.
2002-04-11
Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation.
2002-04-09
PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.
2002-04-05
Mechanism for peroxisome proliferator-activated receptor-alpha activator-induced up-regulation of UCP2 mRNA in rodent hepatocytes.
2002-03-15
A laser flash photolysis study of fenofibric acid in aqueous buffered media: unexpected triplet state inversion in a derivative of 4-alkoxybenzophenone.
2002-03
Prediction of poly(ethylene) glycol-drug eutectic compositions using an index based on the van't Hoff equation.
2002-03
Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes.
2002-03
[Studies on the risk factors for fenofibrate-induced elevation of liver function tests].
2002-02
Pancreatitis associated with simvastatin plus fenofibrate.
2002-02
Pharmacological analysis of wild-type alpha, gamma and delta subtypes of the human peroxisome proliferator-activated receptor.
2002-02
Fish oil feeding alters liver gene expressions to defend against PPARalpha activation and ROS production.
2002-02
PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells.
2002-01-25
Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator- activated receptor alpha agonists.
2002-01-25
Effect of fenofibrate on Chlamydia pneumoniae antibody levels in patients with coronary artery disease.
2002-01-01
Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART.
2002-01
Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia.
2002-01
Dual regulation of mouse Delta(5)- and Delta(6)-desaturase gene expression by SREBP-1 and PPARalpha.
2002-01
Opposite metabolic response to fenofibrate treatment in pregnant and virgin rats.
2002-01
A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration.
2002-01
[Effect of phenofibrate treatment on endothelial dysfunction in patients with history of myocardial infarction in young age].
2002
Treating lipid abnormalities in patients with type 2 diabetes mellitus.
2001-12-20
Increasing high-density lipoprotein cholesterol: an update on fenofibrate.
2001-12-20
Fibrates and homocysteine.
2001-12-18
The transcription of the peroxisome proliferator-activated receptor alpha gene is regulated by protein kinase C.
2001-12-15
Serum uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment.
2001-12
Lipid-lowering trials in diabetes.
2001-12
Peroxisome proliferator-activated receptor a ligands increase lectin-like oxidized low density lipoprotein receptor-1 expression in vascular endothelial cells.
2001-12
[Different serum lipid adjustment drugs for the treatment of hyperlipidemic fatty liver].
2001-12
Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
2001-12
Effects of fenofibrate and gemfibrozil on plasma homocysteine.
2001-11-24
Effects of fenofibrate and gemfibrozil on plasma homocysteine.
2001-11-24
Comparison of DNA damage photoinduced by ketoprofen, fenofibric acid and benzophenone via electron and energy transfer.
2001-11
Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).
2001-11
Regulation of lipid metabolism and gene expression by fenofibrate in hamsters.
2001-10-31
[Pleiotrophic effect of anti-hyperlipemic agents].
2001-10-10
Functional analysis of the transcriptional activity of the mouse phospholipid transfer protein gene.
2001-10-05
[Photoaggravated contact allergy and contact photoallergy caused by ketoprofen: 19 cases].
2001-10
Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol.
2001-10
Variation at position 162 of peroxisome proliferator-activated receptor alpha does not influence the effect of fibrates on cholesterol or triacylglycerol concentrations in hyperlipidaemic subjects.
2001-10
Effects of fenofibrate on lipid parameters in obese rhesus monkeys.
2001-10
Fenofibrate: a new treatment for hyperuricaemia and gout?
2001-10
High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists.
2001-09-21
[Acute hepatitis and drug dermatitis due to fenofibrate (Secalip)].
2001-09
Cerivastatin and gemfibrozil-associated rhabdomyolysis.
2001-09
Fenofibrate-Induced elevation in serum creatinine.
2001-09
Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.
2001-09
Phospholipid composition of high-density lipoproteins reflects lipolysis of triglyceride-rich lipoproteins during hyperlipidemia.
2001-04
Advances in lipid-lowering therapy in atherosclerosis.
2001
[Effects of hypolipidemic therapy on the endothelial dysfunction in patients with myocardial infarction at young age].
2001
Patents

Patents

JP2002509891A
5
JP2002525321A
5
JP2003518129A
11
JP4740881B2
2
JP4767411B2
1
JPH08253416A
1

Sample Use Guides

In Vivo Use Guide
Primary Hypercholesterolemia or Mixed Hyperlipidemia: the initial dose of TRICOR (FENOFIBRATE TABLETS) is 145 mg per day Hypertriglyceridemia: the initial dose is 48 to 145 mg per day
Route of Administration: Oral
In Vitro Use Guide
Fenofibrate may protect against endothelin-1 (ET-1)-induced cardiomyocyte hypertrophy and enhanced adiponectin expression through modulation of PPARα expression in vitro and limitation of daunorubicin cardiotoxicity in vivo, suggesting a novel mechanistic insight into the role of PPARα and adiponectin in cardiachypertrophy and heart failure.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:34:51 GMT 2025
Edited
by admin
on Mon Mar 31 17:34:51 GMT 2025
Record UNII
U202363UOS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Fenofibrate
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
Lipantil
Preferred Name English
Fenofibrate [MI]
Common Name English
Antara
Brand Name English
Isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
Systematic Name English
Fenofibrate [USAN]
Common Name English
Fenofibrate [EP MONOGRAPH]
Common Name English
Lipofen
Brand Name English
Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester
Systematic Name English
Fenofibrate delayed release
Common Name English
Triglide
Brand Name English
Fenofibrate [USP MONOGRAPH]
Common Name English
Fenoglide
Brand Name English
Fenofibrate [VANDF]
Common Name English
Fenofibrate [MART.]
Common Name English
Fenofibrate [USP IMPURITY]
Common Name English
Fenofibrate [JAN]
Common Name English
Fenofibrate micronized
Common Name English
Fenofibrate [EMA EPAR]
Common Name English
Fenofibrate[USP-RS]
Common Name English
Isopropyl 2-[p-(p-chlorobenzoyl)phenoxy]-2-methylpropionate
Systematic Name English
Fenofibrate [WHO-DD]
Common Name English
Lipidil
Brand Name English
Tricor
Brand Name English
Fenofibrate [HSDB]
Common Name English
Fenofibrate [ORANGE BOOK]
Common Name English
Fenofibrate [INN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175375
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
WHO-VATC QC10BA03
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
WHO-ATC C10BA04
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
LIVERTOX NBK548607
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
NCI_THESAURUS C98150
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
WHO-VATC QC10AB05
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
WHO-ATC C10BA03
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
WHO-ATC C10AB05
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
WHO-VATC QC10BA04
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
NDF-RT N0000170118
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
NDF-RT N0000175596
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
NDF-RT N0000170118
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
Code System Code Type Description
INN
3996
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
DAILYMED
U202363UOS
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
EVMPD
SUB07576MIG
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
IUPHAR
7186
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
HSDB
7736
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
NCI_THESAURUS
C29047
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
CAS
49562-28-9
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
ChEMBL
CHEMBL672
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
RXCUI
221100
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
DRUG BANK
DB01039
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
FDA UNII
U202363UOS
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
ECHA (EC/EINECS)
256-376-3
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
CHEBI
5001
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
LACTMED
Fenofibrate
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
RS_ITEM_NUM
1269447
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
MESH
D011345
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
DRUG CENTRAL
1152
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
RXCUI
8703
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
ALTERNATIVE
WIKIPEDIA
FENOFIBRATE
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
MERCK INDEX
m5279
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY Merck Index
EPA CompTox
DTXSID2029874
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
PUBCHEM
3339
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
SMS_ID
100000092530
Created by admin on Mon Mar 31 17:34:51 GMT 2025 , Edited by admin on Mon Mar 31 17:34:51 GMT 2025
PRIMARY
Related Record Type Details
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
OATP1B1
TRANSPORTER -> INHIBITOR
Related Record Type Details
Structure of FENOFIBRIC ACID
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
Structure of Ethyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 1-Methylethyl 2-((2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoyl)oxy)-2-methylpropanoatec
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of FENOFIBRIC ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 4-HYDROXY-4'-CHLOROBENZOPHENONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of Methyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of (4-Chlorophenyl)[4-(1-methylethoxy)phenyl]methanone
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 3-[4-(4-Chlorobenzoyl)phenoxy]-2-butanone
IMPURITY -> PARENT
Structure of 3-[4-(4-Chlorobenzoyl)phenoxy]-2-butanone
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966